Mirxes is a pioneering RNA technology company based in Singapore, dedicated to making diagnostic solutions for the early detection of diseases accessible worldwide. They specialize in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kits for the early detection of cancer and other diseases. Mirxes was founded in the early 2000s, and their breakthrough detection technology for microRNA (miRNA) has revolutionized the field.

Recognizing the potential of miRNA-based clinical applications in addressing unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, Mirxes transitioned their technology from the lab to the clinic. Since then, they have been committed to developing precise multi-cancer early detection solutions and making them readily available to those in need. Mirxes believes in the future of preventive healthcare and continues to drive innovation in the field, with a focus on changing lives by delivering comprehensive preventive healthcare solutions for individuals worldwide